Comparing Malaria Treatments in Uganda
Author Information
Author(s): Bukirwa Hasifa, Yeka Adoke, Kamya Moses R, Talisuna Ambrose, Banek Kristin, Bakyaita Nathan, Rwakimari John Bosco, Rosenthal Philip J, Wabwire-Mangen Fred, Dorsey Grant, Staedke Sarah G
Primary Institution: Uganda Malaria Surveillance Project, Kampala, Uganda
Hypothesis
Is artemether–lumefantrine more effective than amodiaquine + artesunate for treating uncomplicated malaria in children?
Conclusion
Both treatments were highly effective, but artemether–lumefantrine was better at preventing new malaria infections.
Supporting Evidence
- Both treatment regimens were highly efficacious.
- No recrudescences occurred in patients treated with amodiaquine + artesunate.
- The risk of recurrent symptomatic malaria was significantly lower for artemether–lumefantrine.
- Recurrent malaria due to new infections was common.
- Amodiaquine + artesunate and artemether–lumefantrine were both well-tolerated.
Takeaway
This study looked at two medicines for treating malaria in kids. One medicine worked better at stopping kids from getting malaria again.
Methodology
Randomized single-blind controlled trial comparing two treatment regimens.
Potential Biases
Potential bias due to the single-blind design.
Limitations
Patients were only followed for 28 days, which may not capture all recurrences.
Participant Demographics
Children aged 1 to 10 years with confirmed uncomplicated P. falciparum malaria.
Statistical Information
P-Value
0.05
Confidence Interval
95% CI 5.9%–24.2%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website